Whalesbook
Geyanwan Indian Pharma companies layi Q4 FY26 Da forecast pesh karta hai jithe revenue growth di umeed hai, par margin par dabav vadhda dikh reha hai. ICICI Securities da anuman hai ki companies di revenue 7.2% tak vadh sakdi hai, par net profit (PAT) vich 13.3% di significant fall aa sakdi hai.
Revlimid Patent Expiry Da Asar
Is girawat da mukhya karan January 2026 vich Revlimid di patent expiry hai, jida asar Dr. Reddy's Laboratories, Zydus Lifesciences, aur Cipla jaiseyan bade players te vadh payee ga. ICICI Securities da kehna hai ki patent expiry karan operating profit (EBITDA) vich 2.4% da ghatna ho sakda hai, jithe Dr. Reddy's Laboratories nu apney oncology segment vich seedhi revenue loss di samna karna peh sakda hai. Investors ne vi is news nal mixed signals ditte ne, jisda asar stock price volatility vich dikh reha hai.
Growth Drivers: Domestic Market Te Diversification
Is competitive mahol vich vi, kuch companies mazboot rahne wali hain. Lupin Apni Vividh Product Range Aur Mahatvapurna Markets Vich Strong Presence De Nal Achhe Results Pesh Kar Sakdi Hai. Bharat Di Domestic Market Te Zor Den Wali Companies, Jivein Torrent Pharmaceuticals, Apnian Acquisitions, Jivein JB Chemicals & Pharmaceuticals Nu Kharidan Nal, Fayda Utha Sakdiyan Hain. Alkem Laboratories, Jo Ek Aur India-Focused Company Hai, Usda Quarter Mazboot Rehne Da Anuman Hai, Jise Usde Badhte Treatment Areas Aur Mazboot Sales Team Da Support Milega. Nawan Product Launch Gland Pharma Layi Growth Da Mukhya Karan Banega. Tihare Paase, Innovation-Driven Contract Development and Manufacturing Organizations (CDMOs) Jivein Divi's Laboratories, Piramal Pharma, Aur Cohance Nu Mandi Ka Samna Karna Peh Sakda Hai, Jinhe Project Revenues Development Phases Nal Unpredictable Rahnde Han.
Risks Aur Valuations
ICICI Securities Ne Sun Pharmaceutical Industries, Aurobindo Pharma, Alkem Laboratories, Gland Pharma, OneSource, Piramal Pharma, Aur Akums Drugs & Pharmaceuticals Nu Top Stock Picks Vich Shamil Kita Hai. Par, Investors Nu Savdhan Rehna Zaruri Hai. Sector Di Anumanit 7.2% Revenue Growth, Profit Vich Anumanit Girawat Nal Compare Kiti Jaye Ta Margin Tighten Hone Da Sakhat Karan Hai. Dr. Reddy's Aur Cipla Jaisi Companies Layi Revlimid Da Revenue Loss Cover Karan Layi Jaldi Nawan Profitable Drugs Launch Karna Chahida Hai, Jo Regulatory Challenges Nal Bhara Hai. Rivals Jivein Sun Pharma, Jo Development Vich Specialized Drugs Di Wide Range Rakhe Hai, Aur Aurobindo Pharma, Jo Biosimilars Vich Extend Ho Rahi Hai, Steady Growth De Raste Pesh Kar Sakdi Hai. Kai Companies Da Valuation Vadhya Hai, Jithe Bade Players P/E Ratios 20x To 30x Vich Trade Kar Rahe Han, Jithe Growth Targets Miss Hone Da Thoda Room Hai. Exchange Rates Da Badlav Aur Raw Material Costs Vi Profit Nu Ghat Sakde Han. Technical Indicators (RSI) Vi Neutral (45-60) Range Vich Ne, Jo Turant Momentum Di Kami Da Sanket Dinde Han.
Analyst Views Aur Bhavishya
Aage Dekhan, Indian Pharma Sector Specialty Products Aur Biosimilars Te Zor De Reha Hai Taan Jeke Patent Expiry Da Asar Kam Ho Sake. Analysts Cautiously Optimistic Ne, Par Jo Companies Drug Trials Vich Achha Progress Dikhaun Ya Naye Treatment Areas Vich Safalta Nal Entry Kare, Unna Layi Upgrades Di Sambhavna Hai. Sector Da Bhavishya Badalti Hoyi Global Healthcare Needs Aur Domestic Demand Nal Tayar Hovega. Halanki Current Q4 FY26 Vich Chunautiyan Ne, Long-Term Growth Innovation Aur India Ethe Healthcare Access Te Nirbhar Karega.